Cancer News: Prostate
The US FDA has approved the oral drug enzalutamide (trade name: Xtandi), for treating advanced prostate cancer in men who have not yet received chemotherapy.
A study found that men who follow a diet with selenium, calcium and foods rich in lycopene (an antioxidant found in tomatoes) have a lower prostate cancer risk.
Recommendations for active surveillance, which may help low-risk prostate cancer patients avoid the potentially harmful treatment side effects, have been published.
A European study involving over 162,000 men demonstrated the benefits of prostate cancer screenings. However, its leader mentions the risk of over-diagnosis.
ASTRO 2013: Long-term hormonal therapy in intermediate-risk prostate cancer patients does not improve overall survival
A secondary analysis of a historic prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting.
(HealthDay News) -- Most men given radiation to control pain from advanced prostate cancer undergo more treatments than they really need, a new study suggests.
ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate Cancer
Interim and updated analyses showed that radium-223 treatment was associated with significantly prolonged overall survival in men with castration-resistant prostate cancer and bone metastases, resulting in termination of the trial.
Golden age of prostate cancer drug discovery and development as NICE draft guidance recommends new prostate cancer drug
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, London, said: "Advanced prostate cancer is very difficult to treat, and it’s taken a coordinated effort to finally bring new drugs into the pipeline, after decades where there were no options once old-style hormone treatment stopped working."
Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published in the journal Obesity Research & Clinical Practice. In patients with more aggressive forms of prostate cancer, the researchers also found an even stronger correlation between obesity and mortality.
Prostate cancer is second most common cause of cancer death among men, but progress has been made in treatment.
A new test may overcome one of the biggest problems in prostate cancer treatment – telling slow-growing tumours from aggressive ones – according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
A regimen found useful for treating hot flashes in female cancer patients failed to relieve vasomotor symptoms in prostate cancer patients treated with androgen deprivation therapy (ADT), according to a randomized trial.
Cancer Research UK scientists have discovered that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.
Bayer HealthCare announced that the European Commission has granted marketing authorization for radium Ra 223 dichloride solution for injection for the treatment of adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases.
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.
Prostate cancer patients who consumed a low-fat, high fish oil diet had significantly less tissue inflammation and proliferation than patients who ate a typical Western diet, investigators reported.
Men may soon find it easier to decide whether to have surgery for prostate cancer, thanks to two tests that distinguish the aggressive form of the disease from the much milder version.
Researchers have found that prostate cancer can develop in one type of stem cell, then evolve to be maintained by a stem cell that looks very different, making prostate cancer stem cells a "moving target" for treatments. The breakthrough discovery connects directly to the development of future therapeutics that target cancer and was published in the Proceedings of the National Academy of Sciences.
Does the patient have cancer of the prostate gland, commonly called prostate cancer? A question like this is difficult for physicians to answer.
The U.S. Food and Drug Administration approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.
The number of people dying from breast, prostate and bowel cancer will almost halve by 2020, new figures suggest.
Researchers have discovered that men who have a specific protein present in prostate tissue biopsies may be at increased risk of developing prostate cancer. This is according to a study published in the Journal of Clinical Oncology.
Signs of inflammation in initial prostate biopsies may be related to reduced risk of prostate cancer diagnosis in future ones, according to new research on this controversial topic.
Hormone-sensitive metastatic prostate cancer patients, who received the chemotherapy drug docetaxel at the start of standard hormone therapy, lived longer than patients who received hormone therapy alone, according to early clinical trial results.
Structured exercise programs benefit prostate cancer patients treated with androgen deprivation therapy (ADT) in many ways (but have no measurable effects on cardiometabolic risk factors or bone density), a literature review showed.
Opioids (painkillers commonly given during and after surgery) may suppress the immune system's ability to fight cancer cells, leading to a suggestion that supplementing general anesthesia with a spinal or epidural painkiller before a radical prostatectomy reduces a patient's need for opioids after surgery, and this finding was associated with a lower risk of cancer recurrence.
As shown in a study of almost 20,000 men, the death rates from metastatic prostate cancer have been stable for the past 25 years.
Prostate cancer outcomes from radical retropubic prostatectomy may benefit from neuraxial combined with general analgesia, researchers have found.
Prostate cancer is over-diagnosed in 42% of cases, leading to unnecessary treatment and side-effects. Now a tool is being developed against that trend.
Prostate cancer growth and metastasis depends on a particular genome variant, according to new research which can improve understanding of prostate cancer risk.